PDCD1 and melanoma: Our observation mirrors the results generated in melanoma and NSCLC, where a number of companion diagnostic assays have evolved in parallel with the clinical development of PD-1/PD-L1-targeting ICPI.8 Compared to other tumours, however, the level of inter-assay heterogeneity observed in HCC samples appears even more substantial.